trial

A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia

NCTId NCT05542264
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 19 (actual)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2024-02-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
19 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2022-11-15
Primary completion
2024-02-12
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
UlotarontAripiprazole

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor

Sites

4 total
Little Rock, United StatesRogers, United StatesDayton, United StatesSan Antonio, United States

Facts & assertions

4 sourced
Enrollment
19
Phase
PHASE1
Primary Completion Date
2024-02-12
Status
COMPLETED
relationships
The graph out of here
drug
Ulotaront
drug
Aripiprazole
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication